Abbott Laboratories, Inc. (ABT) recently announced that the FDA has approved a change of label for its HeartMate 3 left ventricular assist device (LVAD or heart pump). The development, meant exclusively for patients with an Abbott HeartMate 3 heart pump, aims to provide superior clinical outcomes by eliminating aspirin as part of routine patient management.The labeling update is backed by the data from the company’s ARIES-HM3 trial and has also been approved by regulatory agencies in Canada and the European ...